Long non-coding RNA as the newest perspective biomarkers in cancer
https://doi.org/10.35401/2500-0268-2019-14-2-76-83
Abstract
Long non-coding RNAs (lncRNAs) are a large group of non-coding RNAs (ncRNAs) which are more than 200 nucleotides in length. LncRNAs, as regulation factors, show an important role in complex cellular processes, such as apoptosis, growth, differentiation, proliferation, etc. Recently, the results of many studies have also shown their significant role in carcinogenesis. Endogenous lncRNAs are known to be secreted by tumor cells in human biological fluids in the form of microvesicles, exosomes, or protein complexes, thereby forming circulating lncRNAs that do not degrade under the influence of RNases and are in a stable state. Compared with traditional biomarkers, as proteins circulating lncRNA have several advantages that will allow to consider circulating lncRNA as a new potential biomarker for various diseases. Aberrant expression of lncRNAs was observed in cancer patients. In this context, endogenous lncRNAs can regulate the main characteristics of cancer cells, controlling the expression of oncogenes associated with their suppressive and oncogenic functions. Consequently, circulating lncRNAs can be excellent biomarkers for cancer. Knowledge of the molecular mechanisms by which lncRNAs contribute to the development of cancer will improve our understanding of etiology, and open up horizons for the development of new biomarkers. In this paper, we will analyze current knowledge about the change in the expression profile of circulating lncRNAs in cancer, as well as methods for their detection.
About the Authors
O. A. Beylerli
Bashkir State Medical University, Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Beylerli Ozal Arzuman Ogly – postgraduate student of urology department with ICPE course
450008, Republic Bashkortostan, Ufa, 3, Lenina str.
A. T. Beylerli
Bashkir State Medical University, Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Beyrerli Aferin Tagi Kyzy – resident of the 2nd course, obstetrics and gynaecology department no. 1
450008, Republic Bashkortostan, Ufa, 3, Lenina str.
I. F. Gareev
Bashkir State Medical University, Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Gareev Ilgiz Fanilevich – postgraduate student, department of neurosurgery and medical rehabilitation with ICPE course
450008, Republic Bashkortostan, Ufa, 3, Lenina str.
References
1. Mattick JS. Non-coding RNAs: the architects of eukaryotic complexity. EMBO Reports. 2001;2(11):986–991. https://doi.org/10.1093/embo-reports/kve230
2. Alam T, Medvedeva YA, Jia H, Brown JB, Lipovich L, and Bajic VB. Promoter analysis reveals globally differential regulation of human long noncoding RNA and protein-coding genes. PloS One. 2014;9(10):e109443.
3. van Bakel H and Hughes TR. Establishing legitimacy and function in the new transcriptome. Briefings in Functional Genomics & Proteomics. 2009;8(6):424–436. https://doi.org/10.1093/bfgp/elp037
4. Rinn JL and Chang HY. Genome regulation by long non-coding RNAs. Annual Review of Biochemistry. 2012;81:145–166. https://doi.org/10.1146/annurev-biochem-051410-092902
5. Wilusz JE, Sunwoo H, and Spector DL. Long noncoding RNAs: functional surprises from the RNA world. Genes &Development. 2009;23(13):1494–1504. https://doi.org/10.1101/gad.1800909
6. Flippot R, Malouf GG, Su X, Mouawad R, Spano JP, and Khayat D. Cancer subtypes classification using long non-coding RNA. Oncotarget. 2016;7(33):54082–54093.
7. Derrien T, R. Johnson, Bussotti G et al. The GENCODE v7 catalog of human long noncoding RNAs: analysis of their gene structure, evolution, and expression. Genome Research. 2012;22(9):1775–1789. https://doi.org/10.1101/gr.132159.111
8. Ponting CP, Oliver PL, and Reik W. Evolution and functions of long noncoding RNAs. Cell. 2009;136(4):629–641.
9. Wang Q, Gao S, Li H, Lv M, and Lu C. Long noncoding RNAs (lncRNAs) in triple negative breast cancer. Journal of Cellular Physiology. 2017;9999:1–8. https://doi.org/10.1002/jcp.25830
10. Bartonicek N, Maag JLV, and Dinger ME. Long non-coding RNAs in cancer: mechanisms of action and technological advancements. Molecular Cancer. 2016;15(1):43.
11. Zhang Y, Shields T, Crenshaw T, Hao Y, Moulton T, and Tycko B. Imprinting of human H19: allelespecific CpG methylation, loss of the active allele in Wilms tumor, and potential for somatic allele switching. American Journal of Human Genetics. 1993;53(1):113–124.
12. Shi T, Gao G, and Cao Y. Long noncoding RNAs as novel biomarkers have a promising future in cancer diagnostics. Disease Markers. 2016;2016:10. https://doi.org/10.1155/2016/9085195
13. Ji Q, Liu X, Fu X, et al. Resveratrol inhibits invasion and metastasis of colorectal cancer cells via MALAT1 mediated Wnt/beta-catenin signal pathway. PloS One. 2013;8(11):e78700. https://doi.org/10.1371/ journal.pone.0078700
14. Clark MB, Mercer TR, Bussotti G, et al. Quantitative gene profiling of long noncoding RNAs with targeted RNA sequencing. Nature Methods. 2015; 12 (4): 339–342. https://doi.org/10.1038/nmeth.3321
15. Yarmishyn AA, Kurochkin IV. Long noncoding RNAs: a potential novel class of cancer biomarkers. Front Genet. 2015;6:145. https://doi.org/10.3389/fgene.2015.00145
16. Viereck J1, Thum T2. Circulating Noncoding RNAs as Biomarkers of Cardiovascular Disease and Injury. Circ Res. 2017 Jan 20;120(2):381-399. doi: https://doi.org/10.1161/CIRCRESAHA.116.308434.
17. Eissa S, Matboli M, Essawy NO, Shehta M, Kotb YM. Rapid detection of urinary long non-coding RNA urothelial carcinoma associated one using a PCR-free nanoparticle-based assay. Biomarkers. 2015;20:212–7. https://doi.org/10.3109/1354750X.2015.1062918
18. Zhang H, Zhao L, Wang YX, Xi M, Liu SL, Luo LL. Long non-coding RNA HOTTIP is correlated with progression and prognosis in tongue squamous cell carcinoma. Tumour Biol. 2015;36:8805–9. https://doi.org/10.1007/s13277-015-3645-2
19. Tang H, Wu Z, Zhang J, Su B. Salivary lncRNA as a potential marker for oral squamous cell carcinoma diagnosis. Mol Med Rep. 2013;7:761–6. https://doi. org/10.3892/mmr.2012.1254
20. Kraus TF, Greiner A, Guibourt V, Kretzschmar HA. Long non-coding RNA normalisers in human brain tissue. J Neural Transm (Vienna) 2015;122:1045–54. https://doi.org/10.1007/s00702-014-1352-6
21. Clark MB, Johnston RL, Inostroza-Ponta M, Fox AH, Fortini E, Moscato P, Dinger ME, Mattick JS. Genome – wide analysis of long noncoding RNA stability. Genome Res. 2012;22:885–98. https://doi.org/10.1101/gr.131037.111
22. Zhou X, Yin C, Dang Y, Ye F, Zhang G. Identification of the long non-coding RNA H19 in plasma as a novel biomarker for diagnosis of gastric cancer. Sci Rep. 2015;5:11516. https://doi.org/10.1038/srep11516
23. Kokkat TJ, Patel MS, McGarvey D, LiVolsi VA, Baloch ZW. Archived formalin-fixed paraffin-embedded (FFPE) blocks: A valuable underexploited resource for extraction of DNA, RNA, and protein. Biopreserv Biobank. 2013;11:101–6. https://doi.org/10.1089/bio.2012.0052
24. Qi P, Zhou XY, Du X. Circulating long non-coding RNAs in cancer: current status and future perspectives. Mol Cancer. 2016;15:39. https://doi.org/10.1186/s12943-016-0524-4
25. Qin J, Williams TL, Fernando MR. A novel blood collection device stabilizes cell-free RNA in blood during sample shipping and storage. BMC Res Notes. 2013;6:380. https://doi.org/10.1186/1756-0500-6-380
26. Bell E, et al. A Robust Protocol to Quantify Circulating Cancer Biomarker MicroRNAs. Methods Mol. Biol. —2017. — Vol. 1580. P. 265-279. https://doi.org/10.1007/978-1-4939-6866-4_18
27. Oleksiewicz U, Tomczak K, Woropaj J, Markowska M, Stępniak P, Shah PK. Computational characterisation of cancer molecular profiles derived using next generation sequencing. Contemp Oncol (Pozn). 2015;19(1A):A78– A91. https://doi.org/10.5114/wo.2014.47137
28. Fang Z, Zhang S, Wang Y, et al. Long non-coding RNA MALAT-1 modulates metastatic potential of tongue squamous cell carcinomas partially through the regulation of small proline rich proteins. BMC Cancer. 2016;16:706. https://doi.org/10.1186/s12885-016-2735-x
29. Shi T, Gao G, Cao Y. Long Noncoding RNAs as Novel Biomarkers Have a Promising Future in Cancer Diagnostics. Dis Markers. 2016;2016:9085195. https://doi.org/10.1155/2016/9085195
30. Huang JL, Zheng L, Hu YW, and Wang Q. Characteristics of long non-coding RNA and its relation to hepatocellular carcinoma. Carcinogenesis. 2014;35(3):507–514.
31. Lee GL, Dobi A, and Srivastava S. Prostate cancer: diagnostic performance of the PCA3 urine test. Nature Reviews. Urology. 2011;8(3):123-124. https://doi.org/10.1038/nrurol.2011.10
32. Shappell SB, Fulmer J, Arguello D, Wright BS, Oppenheimer JR, and Putzi MJ. PCA3 urine mRNA testing for prostate carcinoma: patterns of use by community urologists and assay performance in reference laboratory setting. Urology. 2009;73(2):363–368.
33. Hessels D, Klein Gunnewiek JM, van Oort I, et al. DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. European Urology. 2003;44(1):8–15. https://doi.org/10.1016/s0302-2838(03)00201-x
34. Merola R, Tomao L, Antenucci A, et al. PCA3 in prostate cancer and tumor aggressiveness detection on 407 high-risk patients: a National Cancer Institute experience. Journal of Experimental & Clinical Cancer Research: CR. 2015;34(1):15. https://doi.org/10.1186/s13046-015-0127-8
35. Chevli KK, Duff M, Walter P, et al. Urinary PCA3 as a predictor of prostate cancer in a cohort of 3,073 men under-going initial prostate biopsy. The Journal of Urology. 2014;191(6):1743–1748. https://doi.org/10.1016/j.juro.2013.12.005
36. Svoboda M, Slyskova J, Schneiderova M, et al. HOTAIR long non-coding RNA is a negative prognostic factor not only in primary tumors, but also in the blood of colorectal cancer patients. Carcinogenesis. 2014; 35(7):1510–1515. https://doi.org/10.1093/carcin/bgu055
37. Zhao Y, Guo Q, Chen J, Hu J, Wang S, and Sun Y. Role of long non-coding RNA HULC in cell proliferation, apoptosis and tumor metastasis of gastric cancer: a clinical and in vitro investigation. Oncology Reports. 2014;31(1):358–364. https://doi.org/10.3892/or.2013.2850
38. Guo F, Yu F, Wang J, et al. Expression of MALAT1 in the peripheral whole blood of patients with lung cancer. Biomedical Reports. 2015;3(3):309–312. https://doi.org/10.3892/br.2015.422
39. Weber DG, Johnen G, Casjens S, et al. Evaluation of long noncoding RNA MALAT1 as a candidate blood-based biomarker for the diagnosis of non-small cell lung cancer. BMC Research Notes. 2013;6(1):518. https://doi.org/10.1186/1756-0500-6-518
40. Wang F, Ren S, Chen R, et al. Development and prospective multicenter evaluation of the long noncoding RNA MALAT-1 as a diagnostic urinary biomarker for prostate cancer. Oncotarget. 2014; 5(22):11091–11102. https://doi.org/10.18632/oncotarget.2691
41. Peng H, Wang J, Li J, Zhao M, Huang SK, Gu YY, Li Y, Sun XJ, Yang L, Luo Q, Huang CZ. A circulating non-coding RNA panel as an early detection predictor of non-small cell lung cancer. Life Sci. 2016;151:235-242. https://doi.org/10.1016/j.lfs.2016.03.002
42. Tang J, Zhuo H, Zhang X, Jiang R, Ji J, Deng L, Qian X, Zhang F and Sun B. A novel biomarker Linc 00974 interacting with KRT19 promotes proliferation and metastasis in hepatocellular carcinoma. Cell Death Dis. 2014;5(12): e1549. https://doi.org/10.1038cddis.2014.518
Review
For citations:
Beylerli O.A., Beylerli A.T., Gareev I.F. Long non-coding RNA as the newest perspective biomarkers in cancer. Innovative Medicine of Kuban. 2019;(2):76-83. (In Russ.) https://doi.org/10.35401/2500-0268-2019-14-2-76-83
Views:
3858
Email this article 
